Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
Prediagnostic serum biomarkers as early detection tools for pancreatic cancer in a large prospective cohort study.
复制标题
DOI：
10.1371/journal.pone.0094928
复制
发表时间：
2014
期刊：
影响因子：
3.7
通讯作者：
Lokshin AE
中科院分区：
文献类型：
--
作者：
Nolen BM;Brand RE;Prosser D;Velikokhatnaya L;Allen PJ;Zeh HJ;Grizzle WE;Huang Y;Lomakin A;Lokshin AE
由于缺乏有效的筛查工具，胰腺癌的临床治疗受到严重阻碍。对从参加前列腺癌、肺癌、结直肠癌和卵巢癌筛查试验 (PLCO) 的胰腺癌病例中获得的诊断前血清中的 67 种生物标志物进行了评估。在先前的回顾性研究中确定的 CA 19-9、OPN 和 OPG 组合并不有效。诊断前 1 年以上病例获得的血清中 CA 19-9、CEA、NSE、bHCG、CEACAM1 和 PRL 显着改变。 CA 19-9、CA 125、CEA、PRL 和 IL-8 水平与诊断时间呈负相关。使用 PLCO 集的另一半进行的训练/验证研究未能识别出比单独的 CA 19-9 性能显着提高的生物标记物组。当整个 PLCO 集用于以 95% 的特异性 (SP) 进行训练时，CA 19-9、CEA 和 Cyfra 21-1 组在诊断前 <1 年和 >1 年收集的样本中提供显着升高的灵敏度 (SN) 水平，分别为 32.4% 和 29.7%，而单独的 CA 19-9 的 SN 水平为 25.7% 和 17.2%。之前进行的病例/对照研究中确定的大多数生物标志物在诊断前样本中无效，但在诊断前长达 35 个月内确定了一些生物标志物发生了显着改变。两种新衍生的生物标志物组合在 SN 方面比单独的 CA 19-9 具有优势，特别是在诊断前 1 年以上收集的样本中。然而，目前基于生物标记的工具的功效仍然有限。几种生物标志物表现出与诊断时间相关的显着速度，这一观察结果可能为增强早期检测提供巨大潜力。
The clinical management of pancreatic cancer is severely hampered by the absence of effective screening tools. Sixty-seven biomarkers were evaluated in prediagnostic sera obtained from cases of pancreatic cancer enrolled in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO). The panel of CA 19-9, OPN, and OPG, identified in a prior retrospective study, was not effective. CA 19-9, CEA, NSE, bHCG, CEACAM1 and PRL were significantly altered in sera obtained from cases greater than 1 year prior to diagnosis. Levels of CA 19-9, CA 125, CEA, PRL, and IL-8 were negatively associated with time to diagnosis. A training/validation study using alternate halves of the PLCO set failed to identify a biomarker panel with significantly improved performance over CA 19-9 alone. When the entire PLCO set was used for training at a specificity (SP) of 95%, a panel of CA 19-9, CEA, and Cyfra 21-1 provided significantly elevated sensitivity (SN) levels of 32.4% and 29.7% in samples collected <1 and >1 year prior to diagnosis, respectively, compared to SN levels of 25.7% and 17.2% for CA 19-9 alone. Most biomarkers identified in previously conducted case/control studies are ineffective in prediagnostic samples, however several biomarkers were identified as significantly altered up to 35 months prior to diagnosis. Two newly derived biomarker combinations offered advantage over CA 19-9 alone in terms of SN, particularly in samples collected >1 year prior to diagnosis. However, the efficacy of biomarker-based tools remains limited at present. Several biomarkers demonstrated significant velocity related to time to diagnosis, an observation which may offer considerable potential for enhancements in early detection.
登录
查看更多内容
影响因子：
15.8
作者：
Faca VM;Song KS;Wang H;Zhang Q;Krasnoselsky AL;Newcomb LF;Plentz RR;Gurumurthy S;Redston MS;Pitteri SJ;Pereira-Faca SR;Ireton RC;Katayama H;Glukhova V;Phanstiel D;Brenner DE;Anderson MA;Misek D;Scholler N;Urban ND;Barnett MJ;Edelstein C;Goodman GE;Thornquist MD;McIntosh MW;DePinho RA;Bardeesy N;Hanash SM
通讯作者：
Hanash SM
影响因子：
2.6
作者：
Hawass, NED
通讯作者：
Hawass, NED
影响因子：
7.2
作者：
Damiano, J;Bordier, L;Bauduceau, B
通讯作者：
Bauduceau, B
DOI：
10.1111/j.2517-6161.1995.tb02031.x
发表时间：
1995-01-01
影响因子：
5.8
作者：
BENJAMINI, Y;HOCHBERG, Y
通讯作者：
HOCHBERG, Y
影响因子：
2.9
作者：
Chen J;Wu W;Zhen C;Zhou H;Yang R;Chen L;Hu L
通讯作者：
Hu L